Latest from ISC 2017
Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.
More patients receiving VNS experienced enhanced arm movement over a 90-day period.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
Men were more likely than women to be treated with IV tPA within 30 minutes of arrival at a hospital.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
The results provide good evidence for the use of contact aspiration in ischemic stroke.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.
Psychological distress may cause changes within cells that trigger inflammation and oxidative stress, both of which are believed to increase stroke risk.
Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- Brainstem Damage in Epilepsy May Be Biomarker for Increased SUDEP Risk
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Initial Treatment With Ethosuximide Improves Behavioral Outcomes in Childhood Absence Epilepsy
- Bivacizumab Wins Full FDA Approval for Glioblastoma Treatment
- Men With Parkinson Disease More Likely to Have Caregiver
- Diet Linked to Multiple Sclerosis Disability, Diseases Severity